Literature DB >> 1744451

Hormones and pancreatic cancer.

D S Longnecker1.   

Abstract

Several polypeptide hormones have been demonstrated to stimulate or inhibit cell division in the cells of the pancreas. Therefore, receptors for these hormones have been sought in pancreatic carcinomas, and several examples have been reported. In some instances, stimulation of tumor growth by the corresponding peptide has been demonstrated or growth was blocked by a receptor antagonist. Receptors and binding proteins for steroid hormones also have been reported in carcinomas of the pancreas. In experimental carcinogenesis, the growth of preneoplastic lesions and incidence of neoplasms have been influenced by both peptide and steroid hormones in some species. Experimental manipulation of sex steroid hormones has yielded both inhibition and enhancement of growth of human and rat pancreatic cancers, but thus far, clinical trials have failed to document advantageous approaches for steroid or antihormonal therapy. These observations imply that trophic or growth-inhibiting polypeptide and steroid hormones may serve as promoters or inhibitors of carcinogenesis in the pancreas, and may influence the growth of established carcinomas. Receptor blockers may provide a clinical approach for slowing the growth of some cancers.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1744451     DOI: 10.1007/bf02925582

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  23 in total

1.  Gastrointestinal hormones and gastrointestinal and pancreatic carcinomas.

Authors:  C M Townsend; P Singh; J C Thompson
Journal:  Gastroenterology       Date:  1986-10       Impact factor: 22.682

2.  Membrane receptors for peptides in experimental and human pancreatic cancers.

Authors:  M Fekete; A Zalatnai; A M Comaru-Schally; A V Schally
Journal:  Pancreas       Date:  1989       Impact factor: 3.327

3.  Cholecystokinin and gastrin peptides stimulate ODC activity in a rat pancreatic cell line.

Authors:  J L Scemama; L De Vries; L Pradayrol; C Seva; H Tronchere; N Vaysse
Journal:  Am J Physiol       Date:  1989-05

4.  Response to exogenous cholecystokinin of six human gastrointestinal cancers xenografted in nude mice.

Authors:  C Hudd; M C LaRegina; J E Devine; D C Palmer; D R Herbold; M C Beinfeld; F B Gelder; F E Johnson
Journal:  Am J Surg       Date:  1989-04       Impact factor: 2.565

5.  Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin.

Authors:  B Szende; A Zalatnai; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

6.  Effect of bombesin and caerulein on early stages of carcinogenesis induced by azaserine in the rat pancreas.

Authors:  E F Lhoste; D S Longnecker
Journal:  Cancer Res       Date:  1987-06-15       Impact factor: 12.701

7.  Bombesin inhibits growth of human pancreatic adenocarcinoma in nude mice.

Authors:  R W Alexander; J R Upp; G J Poston; C M Townsend; P Singh; J C Thompson
Journal:  Pancreas       Date:  1988       Impact factor: 3.327

8.  Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995.

Authors:  J R Upp; D Olson; G J Poston; R W Alexander; C M Townsend; J C Thompson
Journal:  Am J Surg       Date:  1988-01       Impact factor: 2.565

Review 9.  Androgen influence on exocrine pancreatic cancer.

Authors:  A Andrén-Sandberg
Journal:  Int J Pancreatol       Date:  1989-05

10.  Oophorectomy has no effect on experimental pancreatic carcinogenesis in the Syrian hamster.

Authors:  J F Chester; R I Nicholson; J V Lever; A R Turnbull; D C Britton
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

View more
  9 in total

Review 1.  Energy balance and gastrointestinal cancer: risk, interventions, outcomes and mechanisms.

Authors:  Cornelia M Ulrich; Caroline Himbert; Andreana N Holowatyj; Stephen D Hursting
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-11       Impact factor: 46.802

2.  Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts.

Authors: 
Journal:  Int J Pancreatol       Date:  1994 Oct-Dec

3.  Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer.

Authors:  J J Sharma; B Razvillas; C D Stephens; S G Hilsenbeck; A Sharma; M L Rothenberg
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

4.  Genetic variation in CYP17A1 and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California.

Authors:  Eric J Duell; Elizabeth A Holly; Karl T Kelsey; Paige M Bracci
Journal:  Int J Cancer       Date:  2010-02-01       Impact factor: 7.396

Review 5.  Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis.

Authors:  Wanglong Qiu; Gloria H Su
Journal:  Cancer Metastasis Rev       Date:  2013-06       Impact factor: 9.264

6.  Combination treatment of nitrosamine-induced pancreatic cancers in hamsters with analogs of LH-RH and a bombesin/GRP antagonist.

Authors:  K Szepshazi; G Halmos; K Groot; A V Schally
Journal:  Int J Pancreatol       Date:  1994 Oct-Dec

7.  Expression of receptors for gut peptides in human pancreatic adenocarcinoma and tumour-free pancreas.

Authors:  C Tang; I Biemond; G J Offerhaus; W Verspaget; C B Lamers
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 8.  Recent results in animal models of pancreatic carcinoma: histogenesis of tumors.

Authors:  D S Longnecker; V Memoli; O S Pettengill
Journal:  Yale J Biol Med       Date:  1992 Sep-Oct

9.  Parity and pancreatic cancer risk: evidence from a meta-analysis of twenty epidemiologic studies.

Authors:  Beibei Zhu; Li Zou; Juan Han; Wei Chen; Na Shen; Rong Zhong; Jiaoyuan Li; Xueqin Chen; Cheng Liu; Yang Shi; Xiaoping Miao
Journal:  Sci Rep       Date:  2014-06-17       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.